The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
 
Igor Stukalin
No Relationships to Disclose
 
J Connor Wells
No Relationships to Disclose
 
Jeffrey Graham
No Relationships to Disclose
 
Takeshi Yuasa
No Relationships to Disclose
 
Benoit Beuselinck
Honoraria - Amgen; Bayer; Janssen; Pfizer
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Novartis; Pfizer
 
D. Scott Ernst
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novartis Canada Pharmaceuticals Inc; Roche Canada
 
Neeraj Agarwal
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Tri Le
No Relationships to Disclose
 
Frede Donskov
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Merck Serono; Pfizer
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Georg A. Bjarnason
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Sandy Srinivas
Consulting or Advisory Role - Genentech/Roche; medivation; Novartis; pfizer
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Lori Wood
Research Funding - Aragon Pharmaceuticals (I); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Ravindran Kanesvaran
Honoraria - Astellas Pharma; Janssen; Novartis
Consulting or Advisory Role - Astellas Pharma; Mundipharma; Novartis; pfizer
Research Funding - Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Simon Yuen Fai Fu
No Relationships to Disclose
 
Ian D. Davis
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Exelixis (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst)